DEPLOYThe reference layer for physical AI

Robot model

da Vinci (and Ion)

Intuitive Surgical (NASDAQ: ISRG; founded 1995, Sunnyvale, California) is the dominant incumbent and verified gold standard of surgical robotics. Its da Vinci platform spans the multi-port X and Xi systems, the SP single-port system, and the fifth-generation da Vinci 5, which the FDA cleared via 510(k) on March 14, 2024 with a headline Force Feedback sensing feature, alongside the Ion endoluminal robotic bronchoscopy system cleared in February 2019. As of its SEC Form 10-Q for the quarter ended March 31, 2026, the verified installed base was 11,395 da Vinci systems, up 12 percent year over year and including 1,464 da Vinci 5 units, plus 1,041 Ion systems, up 22 percent, with worldwide procedures growing about 17 percent. Surgical robotics sits in the registry as a deliberate axis-extension: physical AI operating in the medical regulatory regime, where FDA clearance is the verified gating event for maturity, and Intuitive clears it across multiple platforms and generations, placing it at production maturity. On AI substance, da Vinci is a master-slave teleoperated system with shipped analytics-grade AI such as Case Insights and machine-vision interface features, and Force Feedback is a shipped sensing feature rather than autonomy; autonomous suturing and tissue manipulation via vision-language models are research demonstrations on da Vinci hardware, not shipped features, and the 4,000-mile telesurgery demonstration is investigational. The widely cited 43-percent-less-force figure is preclinical and marketing-sourced rather than an outcomes-verified clinical result.

da Vinci (and Ion) is a surgical robot built by Intuitive Surgical.

Machine-readable surfaces

Form factor
surgical
Maturity stage
production
Lifecycle
active
Deployments
0
ID
45105ba4-1c1f-4121-9ad4-bb912db1dcfc

Specs

notes
[object Object],[object Object],[object Object],[object Object]
products
da Vinci multi-port (X / Xi), da Vinci SP single-port, da Vinci 5 (5th-gen, FDA 510(k) Mar 14 2024, Force Feedback), and Ion endoluminal robotic bronchoscopy (FDA Feb 2019).
formFactor
surgical (teleoperated master-slave multi-port + single-port surgical robot; + endoluminal robotic bronchoscopy)

Supply chain

No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model’s suppliers.

Suppliers appear here when verified with at least two strong sources (maker-official / IR / regulatory / standards-body / verified tier-2). Sources are append-only; corrections add new sources rather than rewrite history.

Sources (5)

  1. https://www.sec.gov/Archives/edgar/data/0001035267/000103526726000032/isrg-20260331.htm
  2. https://www.sec.gov/Archives/edgar/data/1035267/000103526726000029/q126ex-991earningsrelease.htm
  3. https://www.globenewswire.com/news-release/2024/03/14/2846718/7637/en/Intuitive-Announces-FDA-Clearance-of-Fifth-Generation-Robotic-System-da-Vinci-5.html
  4. https://www.therobotreport.com/intuitive-demos-4000-mile-telesurgery-with-da-vinci-5-surgical-robot/
  5. https://www.fiercebiotech.com/medtech/intuitive-launches-latest-da-vinci-robot-force-feedback-controls

Common questions

What is da Vinci (and Ion)?
Intuitive Surgical (NASDAQ: ISRG; founded 1995, Sunnyvale, California) is the dominant incumbent and verified gold standard of surgical robotics. Its da Vinci platform spans the multi-port X and Xi systems, the SP single-port system, and the fifth-generation da Vinci 5, which the FDA cleared via 510(k) on March 14, 2024 with a headline Force Feedback sensing feature, alongside the Ion endoluminal robotic bronchoscopy system cleared in February 2019. As of its SEC Form 10-Q for the quarter ended March 31, 2026, the verified installed base was 11,395 da Vinci systems, up 12 percent year over year and including 1,464 da Vinci 5 units, plus 1,041 Ion systems, up 22 percent, with worldwide procedures growing about 17 percent. Surgical robotics sits in the registry as a deliberate axis-extension: physical AI operating in the medical regulatory regime, where FDA clearance is the verified gating event for maturity, and Intuitive clears it across multiple platforms and generations, placing it at production maturity. On AI substance, da Vinci is a master-slave teleoperated system with shipped analytics-grade AI such as Case Insights and machine-vision interface features, and Force Feedback is a shipped sensing feature rather than autonomy; autonomous suturing and tissue manipulation via vision-language models are research demonstrations on da Vinci hardware, not shipped features, and the 4,000-mile telesurgery demonstration is investigational. The widely cited 43-percent-less-force figure is preclinical and marketing-sourced rather than an outcomes-verified clinical result.
Who makes da Vinci (and Ion)?
da Vinci (and Ion) is made by Intuitive Surgical, based in Sunnyvale, California, USA, founded in 1995.
Where is da Vinci (and Ion) deployed?
No verified deployments of da Vinci (and Ion) are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
What is da Vinci (and Ion)'s maturity stage?
da Vinci (and Ion) is at the production stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Production stage means high-volume manufacture and commercial-scale deployments are sustained.